Vera Therapeutics Stock One Year Return
| VERA Stock | USD 42.60 0.55 1.31% |
Vera Therapeutics fundamentals help investors to digest information that contributes to Vera Therapeutics' financial success or failures. It also enables traders to predict the movement of Vera Stock. The fundamental analysis module provides a way to measure Vera Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Vera Therapeutics stock.
Vera |
Vera Therapeutics Company One Year Return Analysis
Vera Therapeutics' One Year Return is the annualized return generated from holding a security for exactly 12 months. The measure is considered to be good short-term measures of fund performance. In other words, it represents the capital appreciation of fund investments over the last year. However when the market is volatile such as in recent years, One Year Return measure can be misleading.
More About One Year Return | All Equity Analysis
One Year Return | = | (Mean of Monthly Returns - 1) | X | 100% |
Although One Year Fund Return indicator can give a sense of overall fund short-term potential, it is recommended to look at mid and long term return measure before selecting a particular fund or ETF. The great way to validate fund short-term performance is to compare it with other similar funds or ETFs for the same 12 months interval.
| Competition |
Based on the recorded statements, Vera Therapeutics has an One Year Return of 0.0%. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Health Care (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).
Vera One Year Return Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vera Therapeutics' direct or indirect competition against its One Year Return to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vera Therapeutics could also be used in its relative valuation, which is a method of valuing Vera Therapeutics by comparing valuation metrics of similar companies.Vera Therapeutics is currently under evaluation in one year return category among its peers.
Vera Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vera Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vera Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Vera Fundamentals
| Return On Equity | -0.65 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 2.39 B | ||||
| Shares Outstanding | 63.32 M | ||||
| Shares Owned By Insiders | 6.83 % | ||||
| Shares Owned By Institutions | 94.68 % | ||||
| Number Of Shares Shorted | 6.52 M | ||||
| Price To Earning | 17.01 X | ||||
| Price To Book | 9.31 X | ||||
| Revenue | 1.86 M | ||||
| EBITDA | (102.01 M) | ||||
| Net Income | (95.99 M) | ||||
| Cash And Equivalents | 131.93 M | ||||
| Cash Per Share | 4.86 X | ||||
| Total Debt | 53.71 M | ||||
| Debt To Equity | 0.10 % | ||||
| Current Ratio | 8.24 X | ||||
| Book Value Per Share | 5.25 X | ||||
| Cash Flow From Operations | (92.18 M) | ||||
| Short Ratio | 6.81 X | ||||
| Earnings Per Share | (2.61) X | ||||
| Target Price | 64.58 | ||||
| Number Of Employees | 82 | ||||
| Beta | 1.02 | ||||
| Market Capitalization | 2.7 B | ||||
| Total Asset | 175.55 M | ||||
| Retained Earnings | (309.1 M) | ||||
| Working Capital | 149.72 M | ||||
| Current Asset | 237.64 M | ||||
| Current Liabilities | 54.04 M | ||||
| Net Asset | 175.55 M |
About Vera Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vera Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vera Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vera Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Vera Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Vera Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Vera Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Vera Therapeutics Stock:Check out Vera Therapeutics Piotroski F Score and Vera Therapeutics Altman Z Score analysis. For information on how to trade Vera Stock refer to our How to Trade Vera Stock guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vera Therapeutics. If investors know Vera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vera Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.61) | Return On Assets (0.33) | Return On Equity (0.65) |
The market value of Vera Therapeutics is measured differently than its book value, which is the value of Vera that is recorded on the company's balance sheet. Investors also form their own opinion of Vera Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Vera Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vera Therapeutics' market value can be influenced by many factors that don't directly affect Vera Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vera Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vera Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vera Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.